1. Cancer IAfRo. Global cancer observatory. 2020.
2. Nardin S, Mora E, Varughese FM, D'Avanzo F, Vachanaram AR, Rossi V, et al. Breast cancer survivorship, quality of life, and late toxicities. Front Oncol 2020; 10: 864.
3. Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the definition of cancer. Mol Cancer Res 2023; 21(11): 1142–7.
4. Bellanger M, Zeinomar N, Tehranifar P, Terry MB. Are global breast cancer incidence and mortality patterns related to country-specific economic development and prevention strategies? J Glob Oncol 2018: 4: 1-16.
5. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA 2005; 293(10): 1245–56.
6. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209–49.
7. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 2020; 77(1): 38–52.
8. Dasgupta P, Baade PD, Aitken JF, Ralph N, Chambers SK, Dunn J. Geographical variations in prostate cancer outcomes: a systematic review of international evidence. Front Oncol 2019; 9: 238.
9. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Ins 2009; 101(19): 1325-9.
10. Gandaglia G, Albers P, Abrahamsson P-A, Briganti A, Catto JW, Chapple CR, et al. Structured population-based prostate-specific antigen screening for prostate cancer: the European Association of Urology position in 2019. Eur Urol 2019; 76(2): 50-142.
11. Kensler KH, Pernar CH, Mahal BA, Nguyen PL, Trinh Q-D, Kibel AS, et al. Racial and ethnic variation in PSA testing and prostate cancer incidence following the 2012 USPSTF recommendation. J Natl Cancer Inst 2021; 113(6): 26-719.
12. Butler SS, Muralidhar V, Zhao SG, Sanford NN, Franco I, Fullerton ZH, et al. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate‐specific antigen screening in 2012. Cancer 2020; 126(4): 717–24.
13. Balta S, Demirkol S, Unlu M, Arslan Z, Celik T. Neutrophil to lymphocyte ratio may be predict of mortality in all conditions. Br J Cancer 2013; 109(12): 3125–6.
14. Trellakis S, Farjah H, Bruderek K, Dumitru C, Hoffmann T, Lang S, et al. Peripheral blood neutrophil granulocytes from patients with head and neck squamous cell carcinoma functionally differ from their counterparts in healthy donors. Int J Immunopathol Pharmacol 2011; 24(3): 683–93.
15. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105(1): 93–103.
16. Sabrkhany S, Griffioen AW, Oude Egbrink MG. The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta 2011; 1815(2): 189–96.
17. Sharma D, Brummel‐Ziedins KE, Bouchard BA, Holmes CE. Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. J Cell Physiol 2014; 229(8): 1005–15.
18. Guclu E, Durmaz Y, Karabay O. Effect of severe sepsis on platelet count and their indices. Afr Health Sci 2013; 13(2): 333–8.
19. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111(6): 1710–7.
20. Gunaldi M, Erdem D, Goksu S, Gunduz S, Okuturlar Y, Tiken E, et al. Platelet distribution width as a predictor of metastasis in gastric cancer patients. J Gastrointest Cancer 2017; 48(4): 341–6.
21. Okuturlar Y, Gunaldi M, Tiken EE, Oztosun B, Inan YO, Ercan T, et al. Utility of peripheral blood parameters in predicting breast cancer risk. Asian Pac J Cancer Prev 2015; 16(6): 2409–12.
22. Yaylaci S, Tosun O, Sahin O, Genc AB, Aydin E, Demiral G, et al. Lack of variation in inflammatory hematological parameters between benign nodular goiter and papillary thyroid cancer. Asian Pac J Cancer Prev 2016; 17(4): 2321–3.
23. Refaai MA, Phipps RP, Spinelli SL, Blumberg N. Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes. Thromb Res 2011; 127(4): 287–91.
24. Ikeguchi M, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukumoto Y, et al. Serum interleukin-6 and-10 levels in patients with gastric cancer. Gastric Cancer 2009; 12(2): 95–100.
25. Qian W, Ge X-X, Wu J, Gong F-R, Wu M-Y, Xu M-D, et al. Prognostic evaluation of resectable colorectal cancer using platelet-associated indicators. Oncol Lett 2019; 18(1): 571–80.
26. Saito H, Shimizu S, Shishido Y, Miyatani K, Matsunaga T, Fujiwara Y. Prognostic significance of the combination of preoperative red cell distribution width and platelet distribution width in patients with gastric cancer. BMC Cancer 2021; 21(1): 1317.
27. Özdemir Ü, Özkubat A. The Diagnostic Importance of RDWLR, PDWLR, and Immature Granulocytes in Colorectal Cancer. Med J SDU 2025; 32(2): 121–8.
28. Huang Y, Cui M-M, Huang Y-X, Fu S, Zhang X, Guo H, et al. Preoperative platelet distribution width predicts breast cancer survival. Cancer Biomark 2018; 23(2): 205–11.
29. Takeuchi H, Abe M, Takumi Y, Hashimoto T, Kobayashi R, Osoegawa A, et al. The prognostic impact of the platelet distribution width-to-platelet count ratio in patients with breast cancer. PLoS One 2017; 12(12): e0189166.
30. Liu C, Zhang H, Qi Q, Zhang B, Yue D, Wang C. The preoperative platelet distribution width: A predictive factor of the prognosis in patients with non‐small cell lung cancer. Thorac Cancer 2020; 11(4): 918–27.